Guenther J Michael, Ward Andrew, Martin Brian J, Cripe Mark, Beard Timothy, Wisco Oliver, Sharma Rohit, Leong Stanley P, Essner Richard, Clark Joseph I, Hamner John, Sickle-Santanello Brenda, Yamamoto Maki
St Elizabeth Physicians General & Vascular Surgery, Edgewood, Kentucky, USA.
University of Tennessee Medical Center, Knoxville, Tennessee, USA.
Cancer Med. 2025 Apr;14(7):e70839. doi: 10.1002/cam4.70839.
Although most patients with cutaneous melanoma (CM) will have a negative sentinel lymph node biopsy (SLNB), up to 20%-30% of these patients will recur. The 31-gene expression profile (31-GEP) test has been prospectively validated to identify patients at low (Class 1A), intermediate (Class 1B/2A), and high (Class 2B) risk of SLN positivity and recurrence.
DECIDE is a prospective, multicenter study to assess the effect of 31-GEP testing on SLNB performance rates in patients with T1-T2 tumors considering SLNB and to study long-term outcomes. Here, we assessed outcomes in patients with a Class 1A 31-GEP result (n = 130).
Of Class 1A patients, 63 had an SLNB, with a 3.2% SLN positivity rate (2/63). No Class 1A patients, regardless of SLN status, experienced a recurrence (2-year median follow-up).
These results are consistent with previous studies that showed the 31-GEP can identify patients at low risk of SLN positivity and recurrence.
尽管大多数皮肤黑色素瘤（CM）患者前哨淋巴结活检（SLNB）结果为阴性，但这些患者中仍有20%-30%会复发。31基因表达谱（31-GEP）检测已得到前瞻性验证，可用于识别前哨淋巴结阳性和复发风险低（1A类）、中（1B/2A类）、高（2B类）的患者。
DECIDE是一项前瞻性多中心研究，旨在评估31-GEP检测对考虑进行SLNB的T1-T2期肿瘤患者SLNB执行率的影响，并研究长期结局。在此，我们评估了31-GEP结果为1A类的患者（n = 130）的结局。
在1A类患者中，63例进行了SLNB，前哨淋巴结阳性率为3.2%（2/63）。无论前哨淋巴结状态如何，均无1A类患者出现复发（中位随访2年）。
这些结果与先前的研究一致，表明31-GEP可识别前哨淋巴结阳性和复发风险低的患者。
